EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results

Sophia Rusch, Petra Stöckert, Stephan Schmid, Tobias Schilling, Martina Müller

Journal of Gastrointestinal and Liver Diseases · 2025

DOI: 10.15403/jgld-6501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Sophia Rusch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic, Hepatitis Delta Virus, Peptide Fragments. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Until recently, the only available treatment option for hepatitis D virus (HDV) was the off-label use of interferon, which is associated with limited efficacy and considerable side effects. The approval of the first HDV-direct antiviral, bulevirtide (BLV), has introduced a targeted therapeutic option for patients with chronic hepatitis delta. We assessed the clinical efficacy of BLV in our HDV patients.

Methods

We conducted a retrospective analysis of all patients diagnosed with HDV infection in our department over the past 10 years. For statistical analysis, we performed multivariate analysis of variance, MANOVA.

Results

26 patients tested positive for HDV antibodies (17 developed chronic hepatitis delta). Eleven patients received BVD. At treatment initiation, liver cirrhosis was present in three patients in the bulevirtide group (MELD-Na: 9–10; Child-Pugh: 5–7) and in three patients in the no bulevirtide group (MELD-Na: 13–18; Child-Pugh: 5–8). Over 12 months of follow-up, bulevirtide recipients showed reductions in alanine aminotransferase (ALT; mean baseline 88 U/L vs 59 U/L; controls 230 U/L vs 206 U/L; MANOVA between-subject effect: p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis D, ChronicHepatitis Delta VirusPeptide FragmentsOligopeptidesHumansRetrospective StudiesMaleFemaleMiddle AgedTreatment OutcomeAdultTime FactorsAgedBiomarkersLiver CirrhosisAlanine Transaminase

Substanzen

Antiviral AgentsPeptide FragmentsBiomarkersAlanine TransaminaseOligopeptides

Autor:innen und Institutionen

  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. sophia.rusch@ukr.de.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. diana.stoeckert@googlemail.com.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. stephan.schmid@ukr.de.
  • Department of Emergency and Intensive Care Medicine, Klinikum Stuttgart, Stuttgart, Germany. T.Schilling@klinikum-stuttgart.de.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. martina.mueller-schilling@ukr.de.

Zitieren

APA

Rusch, S., Stöckert, P., Schmid, S., Schilling, T., & Müller, M. (2025). A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6501

Vancouver

Rusch S, Stöckert P, Schmid S, Schilling T, Müller M. A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-6501

BibTeX
@article{Rusch2025,
  author = {Rusch, Sophia and Stöckert, Petra and Schmid, Stephan and Schilling, Tobias and Müller, Martina},
  title = {A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2025},
  doi = {10.15403/jgld-6501}
}
Kostenlos starten →